Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

By Nikita Chaurasia  | Date: 2020-08-26

Merck’s KEYTRUDA approved to treat PD-L1-positive tumor patients

U.S.-based multinational pharmaceutical giant Merck & Co. Inc. recently announced that its anti-PD-1 therapy named as KEYTRUDA, has received approvals from Japan Pharmaceuticals as well as from Medical Devices Agency (PMDA).

As per the trusted sources, KEYTRUDA monotherapy is approved to treat patients suffering tumors that are PD-L1-positive and have radically unresectable, recurrent or advanced esophageal squamous cell carcinoma (ESCC).

It is to be noted that KEYTRUDA is an anti-PD-1 therapy that improves body’s immune system and also detects and counters tumor cells. The therapy was initially approved to be used at prescribed dosage of 400 mg every six weeks (Q6W), which is operates as an intravenous infusion over 30 minutes across all adult indications, including combination therapy and KEYTRUDA monotherapy, sources claimed.

Dr. Jonathan Cheng, Vice President of oncology clinical research, Merck Research Laboratories reportedly stated that the company is focusing on improving results for as many cancer patients as possible including those with esophageal squamous cell carcinoma, which is a major reason for cancer-related deaths in Japan.

Cheng further added that by using KEYTRUDA the adult patients will now have the provision of a dosing schedule that helps in decreasing the tumor based on how frequently they are at the clinic for treatment.

Jannie Oosthuizen, President at MSD Japan mentioned that over 90% of esophageal cancers are squamous cell carcinomas. Patients who are suffering from advanced disease face poor prognosis and have a critical requirement of better treatment options, he further claimed.

According to the reliable sources, KEYTRUDA’s approval for 400 mg for every six weeks is based on exposure-response analyses and pharmacokinetic modeling. The interim analysis was reportedly based on the pharmacokinetic modeling data, as well as on safety and efficacy data from KEYNOTE-555 which was gathered from a cohort of patients (Cohort B) who use KEYTRUDA 400 mg Q6W.

Source credits-

https://www.merck.com/news/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Tesla to procure nickel from Indonesia through a USD 5 billion deal

Tesla to procure nickel from Indonesia through a USD 5 billion deal

By Nikita Chaurasia

Tesla Inc. has reportedly made contracts worth USD 5 billion with Indonesian nickel manufacturing companies to buy materials for its batteries. For a while now, Indonesia has been trying to get Tesla to invest in setting up a sturdy manufacturing fac...

Amazon Inc. to acquire robotic vacuum maker iRobot for USD 1.7 billion

Amazon Inc. to acquire robotic vacuum maker iRobot for USD 1.7 billion

By Nikita Chaurasia

Credible sources have recently cited that Amazon Inc. is steadily gearing up to acquire iRobot Corporation for USD 61 per share in an all-cash deal that would close the deal at a valuation of USD 1.7 billion as per current estimates. This deal fol...

Robinhood shares surge 13% despite eliminating 23% of its employees

Robinhood shares surge 13% despite eliminating 23% of its employees

By Nikita Chaurasia

Robinhood Markets, Inc. the trading app that popularized one-click transactions, is reportedly laying off nearly 23% of its employees. The company’s CEO Vlad Tenev claimed that the downsizing would affect staff members throughout the company, p...

Bank of England looking into continuously rising inflation in the U.K.

Bank of England looking into continuously rising inflation in the U.K.

By Nikita Chaurasia

The Bank of England has reportedly stated that it will take aggressive measures, if necessary, to prevent the inflation issue from becoming a prolonged challenge. Sources claimed that the central bank might bring an unusual hike of a half-percenta...

Indonesia bans multiple online services for missing regulatory deadline

Indonesia bans multiple online services for missing regulatory deadline

By Nikita Chaurasia

The Indonesian government has reportedly banned access to a series of digital platforms, including PayPal Holdings Inc., Steam, Epic Games Inc., and Yahoo Inc., for failing to comply with the country's new mandate regarding content review policie...